Aspen Pharmacare (OTCMKTS:APNHY) Upgraded to “Buy” at Zacks Investment Research

Aspen Pharmacare (OTCMKTS:APNHY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, February 8th. The brokerage currently has a $24.00 price target on the stock. Zacks Investment Research‘s price objective points to a potential downside of 0.08% from the company’s previous close.

According to Zacks, “Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa. “

Shares of Aspen Pharmacare (OTCMKTS:APNHY) opened at $24.02 on Thursday. Aspen Pharmacare has a 1-year low of $19.45 and a 1-year high of $24.60. The company has a current ratio of 1.09, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67.

ILLEGAL ACTIVITY NOTICE: “Aspen Pharmacare (OTCMKTS:APNHY) Upgraded to “Buy” at Zacks Investment Research” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/19/aspen-pharmacare-apnhy-upgraded-to-buy-by-zacks-investment-research.html.

About Aspen Pharmacare

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies branded and generic pharmaceutical products, infant nutritionals, and consumer healthcare products. The company offers various branded products for a range of therapeutic categories, including anaesthetics, analgesics, anti-retrovirals, blood and haemopoetic, cardio vascular system, central nervous system, endocrine system, gastro-intestinal tract, infant milk formulations, musculo-skeletal agents, NSAIDs, oncology, oral hygiene, respiratory system, and urinary tract system, as well as ear, nose, and throat.

Get a free copy of the Zacks research report on Aspen Pharmacare (APNHY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aspen Pharmacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Pharmacare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply